X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES GLENMARK PHARMA ALKEM LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x - 20.0 - View Chart
P/BV x 6.6 3.5 189.1% View Chart
Dividend Yield % 0.7 0.3 218.1%  

Financials

 ALKEM LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
GLENMARK PHARMA
Mar-18
ALKEM LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,589930 170.9%   
Low Rs1,232517 238.1%   
Sales per share (Unadj.) Rs417.5322.6 129.4%  
Earnings per share (Unadj.) Rs56.328.5 197.6%  
Cash flow per share (Unadj.) Rs64.739.2 165.1%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.3 325.8%  
Book value per share (Unadj.) Rs292.9183.0 160.1%  
Shares outstanding (eoy) m119.57282.17 42.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.2 150.6%   
Avg P/E ratio x25.125.4 98.6%  
P/CF ratio (eoy) x21.818.5 118.0%  
Price / Book Value ratio x4.84.0 121.8%  
Dividend payout %22.67.0 321.4%   
Avg Mkt Cap Rs m168,653204,206 82.6%   
No. of employees `000NA13.7 0.0%   
Total wages/salary Rs m9,17118,718 49.0%   
Avg. sales/employee Rs ThNM6,636.8-  
Avg. wages/employee Rs ThNM1,364.7-  
Avg. net profit/employee Rs ThNM586.1-  
INCOME DATA
Net Sales Rs m49,91591,031 54.8%  
Other income Rs m1,645914 180.0%   
Total revenues Rs m51,56191,945 56.1%   
Gross profit Rs m8,48216,154 52.5%  
Depreciation Rs m1,0063,019 33.3%   
Interest Rs m6712,856 23.5%   
Profit before tax Rs m8,45111,193 75.5%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6063,155 50.9%   
Profit after tax Rs m6,7318,039 83.7%  
Gross profit margin %17.017.7 95.8%  
Effective tax rate %19.028.2 67.4%   
Net profit margin %13.58.8 152.7%  
BALANCE SHEET DATA
Current assets Rs m27,06269,887 38.7%   
Current liabilities Rs m15,32432,879 46.6%   
Net working cap to sales %23.540.7 57.8%  
Current ratio x1.82.1 83.1%  
Inventory Days Days6781 81.7%  
Debtors Days Days4193 44.2%  
Net fixed assets Rs m12,61028,892 43.6%   
Share capital Rs m239282 84.7%   
"Free" reserves Rs m34,49051,353 67.2%   
Net worth Rs m35,02751,635 67.8%   
Long term debt Rs m1,21241,418 2.9%   
Total assets Rs m54,387125,954 43.2%  
Interest coverage x13.64.9 276.5%   
Debt to equity ratio x00.8 4.3%  
Sales to assets ratio x0.90.7 127.0%   
Return on assets %13.68.6 157.3%  
Return on equity %19.215.6 123.4%  
Return on capital %24.915.1 164.6%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56336,317 18.1%   
Fx outflow Rs m3,0129,720 31.0%   
Net fx Rs m3,55226,598 13.4%   
CASH FLOW
From Operations Rs m7,25916,481 44.0%  
From Investments Rs m1,864-10,133 -18.4%  
From Financial Activity Rs m-9,273-4,685 197.9%  
Net Cashflow Rs m-1501,770 -8.5%  

Share Holding

Indian Promoters % 66.9 48.3 138.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 6.9 479.7%  
FIIs % 0.0 34.4 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 10.5 -  
Shareholders   68,381 56,727 120.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  DIVIS LABORATORIES  ALEMBIC LTD  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open on a Positive Note; Realty & Auto Stocks Lead(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.2% while the Hang Seng is up 1.6%.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Dec 12, 2018 10:11 AM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS